MDRX Stock Recent News Allscripts Healthcare Solutions (MDRX)

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 11:12 PM

Allscripts Healthcare Solutions (MDRX) 12.44 $MDRX

Cerner (CERN) Touches 52-Week High on Growing Backlog - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 12:00PM CST
Shares of Cerner Corp. (CERN) reached a 52-week high of $64.62 on Nov 13, 2014.
QSII: 14.89 (-0.10), MDRX: 12.44 (-0.02), MRGE: 3.24 (+0.15), CERN: 64.31 (-0.22)

MaineGeneral Health renews, expands relationship with Allscripts
M2 - Fri Nov 14, 10:40AM CST
MaineGeneral Health, headquartered in Augusta, Maine, has announced a significant renewal of its commitment to Allscripts (NASDAQ: MDRX) and has agreed to continue to leverage Allscripts Sunrise and Allscripts TouchWorks electronic health records through 2022.
MDRX: 12.44 (-0.02)

21.7% Return Seen to Date on SmarTrend Allscripts Healthcare Solutions Call (MDRX)
Comtex SmarTrend(R) - Thu Nov 13, 10:05AM CST
SmarTrend identified a Downtrend for Allscripts Healthcare Solutions (NASDAQ:MDRX) on August 4th, 2014 at $15.49. In approximately 3 months, Allscripts Healthcare Solutions has returned 21.67% as of today's recent price of $12.13.
MDRX: 12.44 (-0.02)

Forbes Media Hosts Third Annual "Forbes Healthcare Summit 2014: Smart Data Transforming Lives"
Business Wire - Thu Nov 13, 8:45AM CST
--More than 200 Industry Leaders to Participate, including Robert Hugin, Chairman and CEO of Celgene; Eric Schadt, director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai School of Medicine; Patrick Soon-Shiong, Chairman and CEO of NantHealth; Steve Forbes, Chairman and Editor-in-Chief of Forbes; Jonathan Bush, CEO and President of athenahealth; Richard Klausner, Chief Medical Officer of Illumina; Alan Auerbach, Chairman, President and CEO of Puma Biotechnology; Paul Bleicher, CEO of Optum Labs; Glen de Vries, President of Medidata; George Yancopoulos, Chief Scientific Officer of Regeneron; Dan Hilferty, President and CEO of Independence Blue Cross; Robert Green, Director of Genomes2People at Harvard Medical School; John Scully of Scully Partners; Joe Herring, Chairman and CEO of Covance; Brandon Hull of Cardinal Partners; and Robert Kocher of Venrock
UNH: 95.11 (-0.79), MDRX: 12.44 (-0.02), PBYI: 216.22 (-23.27), CELGZ: 3.28 (+0.10)

Reveal Insider Trading for Twitter, Micron, Allscripts, SolarCity, MannKind, and Plug Power
PR Newswire - Thu Nov 13, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Twitter (NYSE:TWTR), Micron (NASDAQ:MU), Allscripts (NASDAQ:MDRX), SolarCity (NASDAQ:SCTY), MannKind (NASDAQ:MNKD), and Plug Power (NASDAQ

LUG).
MU: 32.62 (-0.32), SCTY: 53.02 (+2.18), PLUG: 3.72 (-0.34), MDRX: 12.44 (-0.02), MNKD: 6.16 (-0.02), TWTR: 41.85 (+1.81)

MaineGeneral Health renews and expands relationship with Allscripts
PR Newswire - Thu Nov 13, 7:01AM CST
MaineGeneral Health (MaineGeneral), headquartered in Augusta, Maine, has announced a significant renewal of its commitment to Allscripts (NASDAQ: MDRX) and has agreed to continue to leverage Allscripts Sunrise and Allscripts TouchWorks electronic health records (EHR) through 2022. MaineGeneral also announced it has selected Allscripts FollowMyHealth(TM) as its patient engagement platform to support population health management, improve patient communications and deliver positive care outcomes.
MDRX: 12.44 (-0.02)

Allscripts Healthcare and CHI Sign Hosting Solution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:40PM CST
By utilizing Allscripts Healthcare Solutions, Inc. (MDRX) Hosting Solution, Catholic Health Initiatives expects improved system availability, reduced IT infrastructure expenditures as well as enhanced end user performance.
GWPH: 75.63 (-0.21), ABAX: 54.80 (-0.21), MDRX: 12.44 (-0.02), MRGE: 3.24 (+0.15)

Catholic Health Initiatives picks Allscripts remote hosting solution
M2 - Wed Nov 12, 11:29AM CST
Allscripts (NASDAQ: MDRX) said it has announced that Catholic Health Initiatives has selected Allscripts Hosting Solution to provide enterprise-wide information technology through 2020.
MDRX: 12.44 (-0.02)

Allscripts to Present at the 2014 Credit Suisse Healthcare Conference
PR Newswire - Tue Nov 11, 6:26PM CST
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) today announced that Richard J. Poulton, Chief Financial Officer, will present at the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, Ariz., on Wednesday, November 12, 2014 at 1:00 p.m. MST.
MDRX: 12.44 (-0.02)

Catholic Health Initiatives chooses Allscripts Remote Hosting Solution
PR Newswire - Tue Nov 11, 7:01AM CST
Allscripts (NASDAQ:MDRX) has announced that Catholic Health Initiatives (CHI), one of the largest health systems in the nation, has selected Allscripts Hosting Solution to provide enterprise-wide information technology (IT) through 2020.
MDRX: 12.44 (-0.02)

Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TNGO: 13.24 (+0.61), PRSC: 35.59 (-0.90), FNGN: 32.91 (+0.55), LACO: 7.10 (-0.01), MSON: 11.66 (-0.17), SLXP: 102.32 (+5.33), FNHC: 24.73 (-0.32), MDRX: 12.44 (-0.02), PCMI: 9.07 (+0.13), UBNT: 29.73 (+1.01), PFMT: 6.85 (unch), ICPT: 162.58 (+3.72), ANDE: 54.45 (+0.33), ACTA: 16.71 (unch)

Allscripts Healthcare Solutions Set to Possibly Rebound After Yesterday's Selloff of 14.83%
Comtex SmarTrend(R) - Fri Nov 07, 3:57PM CST
Allscripts Healthcare Solutions (NASDAQ:MDRX) traded in a range yesterday that spanned from a low of $11.00 to a high of $11.76. Yesterday, the shares fell 14.8%, which took the trading range below the 3-day low of $13.40 on volume of 16.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDRX: 12.44 (-0.02)

Allscripts Healthcare Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 12:30PM CST
Allscripts Healthcare Solutions, Inc. (MDRX) posted adjusted earnings of 2 cents per share in the third quarter of 2014 which missed the Zacks Consensus Estimate by 3 cents.
GWPH: 75.63 (-0.21), ABAX: 54.80 (-0.21), MDRX: 12.44 (-0.02), MRGE: 3.24 (+0.15)

Allscripts Healthcare Solutions (MDRX) Stock Lower After Earnings Miss
at The Street - Fri Nov 07, 9:20AM CST
Allscripts Healthcare Solutions (MDRX) is falling Friday after missing analysts' estimates for earnings and revenue in the third quarter.
MDRX: 12.44 (-0.02)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.60 (+0.21), ANET: 77.69 (+0.72), TKMR: 16.41 (+0.14), ORBC: 6.48 (+0.01), MDRX: 12.44 (-0.02), RMTI: 10.52 (-0.49), CTIC: 2.13 (-0.02), SHLD: 37.31 (-0.49), UBNT: 29.73 (+1.01), RIG: 26.05 (-0.24), KGC: 2.71 (+0.19), APT: 2.92 (+0.05), ANF: 28.90 (unch), MITK: 3.65 (+0.11), ZNGA: 2.77 (+0.04), CNET: 1.96 (-0.10), KING: 16.12 (+1.07), NETE: 1.42 (+0.04), SLXP: 102.32 (+5.33), RPRX: 9.34 (-0.26), NADL: 4.28 (+0.11), PGNX: 6.33 (-0.12), AVNR: 13.13 (-0.01), FSLR: 48.49 (+0.93), DVA: 75.66 (-1.38), NDLS: 23.48 (+0.01), ICPT: 162.58 (+3.72), AGIO: 84.06 (-2.43), PLNR: 6.69 (+0.02)

Allscripts -19.2% on Q3 miss, bookings drop
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:01AM CST

MDRX: 12.44 (-0.02)

Allscripts Healthcare Solutions' (MDRX) CEO Paul Black on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 10:20PM CST

MDRX: 12.44 (-0.02)

AllScripts Healthcare reports 3Q loss
AP - Thu Nov 06, 5:44PM CST
CHICAGO (AP) — Allscripts Healthcare Solutions Inc. on Thursday posted lower-than-expected third-quarter results and the stock of the electronic health records company tumbled in extended trading.
MDRX: 12.44 (-0.02)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:36PM CST

YUME: 5.14 (+0.04), UBNT: 29.73 (+1.01), APT: 2.92 (+0.05), ECOM: 18.85 (-0.05), KTOS: 5.40 (+0.03), SLXP: 102.32 (+5.33), MRC: 21.96 (+0.41), MDRX: 12.44 (-0.02), SSE: 11.28 (+0.09), NKTR: 13.63 (-0.23)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Miranda Lambert Lights Up Red Kettle Campaign

By Logan Wright Updated Oct 25, 2026 Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...